• Sprint Bioscience posted a wider Q2 operating loss of SEK 16.6 million, deteriorating from SEK 6.8 million a year earlier.
• Net sales were nil, down from SEK 13.9 million in the year-ago quarter; operating cash flow was SEK -14.6 million.
• H1 operating loss widened to SEK 30.9 million from SEK 11.8 million, while operating cash flow fell to SEK -33 million.
• Cash and cash equivalents rose to SEK 93.3 million versus SEK 24.7 million at end-June 2025.
• Signed a deal with Lilly TuneLab; CEO Johan Emilsson cited strong partnering interest around oncology, immunology and inflammation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sprint Bioscience AB published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.